Cargando…
Antitumor HPV E7-specific CTL activity elicited by in vivo engineered exosomes produced through DNA inoculation
We recently proved that exosomes engineered in vitro to deliver high amounts of HPV E7 upon fusion with the Nef(mut) exosome-anchoring protein elicit an efficient anti-E7 cytotoxic T lymphocyte immune response. However, in view of a potential clinic application of this finding, our exosome-based imm...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491702/ https://www.ncbi.nlm.nih.gov/pubmed/28694699 http://dx.doi.org/10.2147/IJN.S131309 |
_version_ | 1783247183791783936 |
---|---|
author | Di Bonito, Paola Chiozzini, Chiara Arenaccio, Claudia Anticoli, Simona Manfredi, Francesco Olivetta, Eleonora Ferrantelli, Flavia Falcone, Emiliana Ruggieri, Anna Federico, Maurizio |
author_facet | Di Bonito, Paola Chiozzini, Chiara Arenaccio, Claudia Anticoli, Simona Manfredi, Francesco Olivetta, Eleonora Ferrantelli, Flavia Falcone, Emiliana Ruggieri, Anna Federico, Maurizio |
author_sort | Di Bonito, Paola |
collection | PubMed |
description | We recently proved that exosomes engineered in vitro to deliver high amounts of HPV E7 upon fusion with the Nef(mut) exosome-anchoring protein elicit an efficient anti-E7 cytotoxic T lymphocyte immune response. However, in view of a potential clinic application of this finding, our exosome-based immunization strategy was faced with possible technical difficulties including industrial manufacturing, cost of production, and storage. To overcome these hurdles, we designed an as yet unproven exosome-based immunization strategy relying on delivery by intramuscular inoculation of a DNA vector expressing Nef(mut) fused with HPV E7. In this way, we predicted that the expression of the Nef(mut)/E7 vector in muscle cells would result in a continuous source of endogenous (ie, produced by the inoculated host) engineered exosomes able to induce an E7-specific immune response. To assess this hypothesis, we first demonstrated that the injection of a Nef(mut)/green fluorescent protein-expressing vector led to the release of fluorescent exosomes, as detected in plasma of inoculated mice. Then, we observed that mice inoculated intramuscularly with a vector expressing Nef(mut)/E7 developed a CD8(+) T-cell immune response against both Nef and E7. Conversely, no CD8(+) T-cell responses were detected upon injection of vectors expressing either the wild-type Nef isoform of E7 alone, most likely a consequence of their inefficient exosome incorporation. The production of immunogenic exosomes in the DNA-injected mice was formally demonstrated by the E7-specific CD8(+) T-cell immune response we detected in mice inoculated with exosomes isolated from plasma of mice inoculated with the Nef(mut)/E7 vector. Finally, we provide evidence that the injection of Nef(mut)/E7 DNA led to the generation of effective antigen-specific cytotoxic T lymphocytes whose activity was likely part of the potent, therapeutic antitumor effect we observed in mice implanted with TC-1 tumor cells. In summary, we established a novel method to generate immunogenic exosomes in vivo by the intramuscular inoculation of DNA vectors expressing the exosome-anchoring protein Nef(mut) and its derivatives. |
format | Online Article Text |
id | pubmed-5491702 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-54917022017-07-10 Antitumor HPV E7-specific CTL activity elicited by in vivo engineered exosomes produced through DNA inoculation Di Bonito, Paola Chiozzini, Chiara Arenaccio, Claudia Anticoli, Simona Manfredi, Francesco Olivetta, Eleonora Ferrantelli, Flavia Falcone, Emiliana Ruggieri, Anna Federico, Maurizio Int J Nanomedicine Original Research We recently proved that exosomes engineered in vitro to deliver high amounts of HPV E7 upon fusion with the Nef(mut) exosome-anchoring protein elicit an efficient anti-E7 cytotoxic T lymphocyte immune response. However, in view of a potential clinic application of this finding, our exosome-based immunization strategy was faced with possible technical difficulties including industrial manufacturing, cost of production, and storage. To overcome these hurdles, we designed an as yet unproven exosome-based immunization strategy relying on delivery by intramuscular inoculation of a DNA vector expressing Nef(mut) fused with HPV E7. In this way, we predicted that the expression of the Nef(mut)/E7 vector in muscle cells would result in a continuous source of endogenous (ie, produced by the inoculated host) engineered exosomes able to induce an E7-specific immune response. To assess this hypothesis, we first demonstrated that the injection of a Nef(mut)/green fluorescent protein-expressing vector led to the release of fluorescent exosomes, as detected in plasma of inoculated mice. Then, we observed that mice inoculated intramuscularly with a vector expressing Nef(mut)/E7 developed a CD8(+) T-cell immune response against both Nef and E7. Conversely, no CD8(+) T-cell responses were detected upon injection of vectors expressing either the wild-type Nef isoform of E7 alone, most likely a consequence of their inefficient exosome incorporation. The production of immunogenic exosomes in the DNA-injected mice was formally demonstrated by the E7-specific CD8(+) T-cell immune response we detected in mice inoculated with exosomes isolated from plasma of mice inoculated with the Nef(mut)/E7 vector. Finally, we provide evidence that the injection of Nef(mut)/E7 DNA led to the generation of effective antigen-specific cytotoxic T lymphocytes whose activity was likely part of the potent, therapeutic antitumor effect we observed in mice implanted with TC-1 tumor cells. In summary, we established a novel method to generate immunogenic exosomes in vivo by the intramuscular inoculation of DNA vectors expressing the exosome-anchoring protein Nef(mut) and its derivatives. Dove Medical Press 2017-06-23 /pmc/articles/PMC5491702/ /pubmed/28694699 http://dx.doi.org/10.2147/IJN.S131309 Text en © 2017 Di Bonito et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Di Bonito, Paola Chiozzini, Chiara Arenaccio, Claudia Anticoli, Simona Manfredi, Francesco Olivetta, Eleonora Ferrantelli, Flavia Falcone, Emiliana Ruggieri, Anna Federico, Maurizio Antitumor HPV E7-specific CTL activity elicited by in vivo engineered exosomes produced through DNA inoculation |
title | Antitumor HPV E7-specific CTL activity elicited by in vivo engineered exosomes produced through DNA inoculation |
title_full | Antitumor HPV E7-specific CTL activity elicited by in vivo engineered exosomes produced through DNA inoculation |
title_fullStr | Antitumor HPV E7-specific CTL activity elicited by in vivo engineered exosomes produced through DNA inoculation |
title_full_unstemmed | Antitumor HPV E7-specific CTL activity elicited by in vivo engineered exosomes produced through DNA inoculation |
title_short | Antitumor HPV E7-specific CTL activity elicited by in vivo engineered exosomes produced through DNA inoculation |
title_sort | antitumor hpv e7-specific ctl activity elicited by in vivo engineered exosomes produced through dna inoculation |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491702/ https://www.ncbi.nlm.nih.gov/pubmed/28694699 http://dx.doi.org/10.2147/IJN.S131309 |
work_keys_str_mv | AT dibonitopaola antitumorhpve7specificctlactivityelicitedbyinvivoengineeredexosomesproducedthroughdnainoculation AT chiozzinichiara antitumorhpve7specificctlactivityelicitedbyinvivoengineeredexosomesproducedthroughdnainoculation AT arenaccioclaudia antitumorhpve7specificctlactivityelicitedbyinvivoengineeredexosomesproducedthroughdnainoculation AT anticolisimona antitumorhpve7specificctlactivityelicitedbyinvivoengineeredexosomesproducedthroughdnainoculation AT manfredifrancesco antitumorhpve7specificctlactivityelicitedbyinvivoengineeredexosomesproducedthroughdnainoculation AT olivettaeleonora antitumorhpve7specificctlactivityelicitedbyinvivoengineeredexosomesproducedthroughdnainoculation AT ferrantelliflavia antitumorhpve7specificctlactivityelicitedbyinvivoengineeredexosomesproducedthroughdnainoculation AT falconeemiliana antitumorhpve7specificctlactivityelicitedbyinvivoengineeredexosomesproducedthroughdnainoculation AT ruggierianna antitumorhpve7specificctlactivityelicitedbyinvivoengineeredexosomesproducedthroughdnainoculation AT federicomaurizio antitumorhpve7specificctlactivityelicitedbyinvivoengineeredexosomesproducedthroughdnainoculation |